What question did this study set out to answer?

The aim is to determine whether adaptive servo-ventilation therapy improves prognosis in heart failure patients across different levels of sleep-disordered breathing severity.

January 1, 2011Circulation JournalOpen Access

Short-Term Prognosis of Adaptive Servo-Ventilation Therapy in Patients With Heart Failure

View Full Paper

Ask AI

Bookmark

Why the study?

Does adaptive servo-ventilation (ASV) therapy reduce death or heart failure hospitalization in patients with heart failure, regardless of the severity of sleep-disordered breathing?

Population

88 consecutive patients diagnosed with heart failure and a hospital admission in the 6 months prior to…

Comparison

Adaptive servo-ventilation therapy during the… vs No ASV treatment.

Design

Cohort

Follow-up

12 months

Authors

TKTakashi KoyamaMiyagi Prefectural Hospital Organization HWHiroyuki WatanabeKanazawa University GIGen IgarashiJikei University School of Medicine

Discussion

Member takes

Implication

ASV may benefit heart failure patients across sleep-disordered breathing severities; observational data leaves open need for randomized confirmation.

Key Points

The aim is to determine whether adaptive servo-ventilation therapy improves prognosis in heart failure patients across different levels of sleep-disordered breathing severity.
88 patients were divided into 4 groups based on adaptive servo-ventilation therapy and severity of sleep-disordered breathing.
The incidence of heart failure, BNP levels, and left ventricular ejection fraction were monitored over 12 months.
Fewer heart failure events were recorded in ASV-treated patients.
An increase in left ventricular ejection fraction was noted in ASV-treated patients.
A decrease in brain natriuretic peptide levels occurred in ASV-treated patients.

Structured PICO

Does adaptive servo-ventilation (ASV) therapy reduce death or heart failure hospitalization in patients with heart failure, regardless of the severity of sleep-disordered breathing?

Population

88 consecutive patients diagnosed with heart failure (NYHA class II or III, LVEF <55%) and a hospital admission in the 6 months prior to therapy initiation. Excluded: patients experiencing decompensated HF or who had recovered from acute HF.

Intervention

Adaptive servo-ventilation (ASV) therapy during the night (device usage >4 hours per night) for 12 months.

Comparator

No ASV treatment (patients who could not use the ASV device because of the discomfort of either wearing a mask or the positive airway pressure).

Outcome

Proportion of patients who died or were admitted to hospital because of heart failure at 12 months.composite

Limitations

Observational trial design introduces potential bias
Beneficial effect was observed only in HF patients who could tolerate the ASV device (selection bias)

Cite This Study

Koyama et al. (2011) studied this question.

synapsesocial.com/papers/6a21ec7a4ae3d5108796dafc https://doi.org/10.1253/circj.cj-10-0956

Topics

HFrEF treatment Heart failure

View Full Paper

Ask AI

Bookmark

Implication

ASV may benefit heart failure patients across sleep-disordered breathing severities; observational data leaves open need for randomized confirmation.

Short-Term Prognosis of Adaptive Servo-Ventilation Therapy in Patients With Heart Failure

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

Short-Term Prognosis of Adaptive Servo-Ventilation Therapy in Patients With Heart Failure

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider